A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

NCT07540897 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Narcolepsy Type 1

Interventions

DRUG: ALKS 2680 Dose 1
DRUG: ALKS 2680 Dose 2
DRUG: Placebo

Sponsor

Alkermes, Inc.